HCV

Potential utility of the Genedrive point-of-care test for HCV RNA detection
Alba Llibre, Yusuke Shimakawa, Darragh Duffy

Gut Oct 2019, 68 (10) 1903-1904; DOI: 10.1136/gutjnl-2018-317218
What is required from HCV point-of-care tests to reduce the burden of hepatitis C infection? ‘Development and clinical validation of the genedrive point-of-care test for qualitative detection of hepatitis C virus’
Maud Lemoine, Hans L Tillmann

Gut Nov 2018, 67 (11) 1916-1917; DOI: 10.1136/gutjnl-2018-316438
miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis
Nicolaas Van Renne, Armando Andres Roca Suarez, Francois H T Duong, Claire Gondeau, Diego Calabrese, Nelly Fontaine, Amina Ababsa, Simonetta Bandiera, Tom Croonenborghs, Nathalie Pochet, Vito De Blasi, Patrick Pessaux, Tullio Piardi, Daniele Sommacale, Atsushi Ono, Kazuaki Chayama, Masashi Fujita, Hidewaki Nakagawa, Yujin Hoshida, Mirjam B Zeisel, Markus H Heim, Thomas F Baumert, Joachim Lupberger

Gut May 2018, 67 (5) 953-962; DOI: 10.1136/gutjnl-2016-312270
Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model
Hiroshi Yokokawa, Atsunori Higashino, Saori Suzuki, Masaki Moriyama, Noriko Nakamura, Tomohiko Suzuki, Ryosuke Suzuki, Koji Ishii, Kouji Kobiyama, Ken J Ishii, Takaji Wakita, Hirofumi Akari, Takanobu Kato

Gut Feb 2018, 67 (2) 372-379; DOI: 10.1136/gutjnl-2016-312208
Intriguing structure of the HCV particle
Agata Budkowska

Gut Aug 2017, 66 (8) 1351-1352; DOI: 10.1136/gutjnl-2016-313184
OC-010 Final efficacy and safety in hcv genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin: topaz-i results from the united kingdom and ireland
D Forton, A Ustianowski, R Aspinall, S Ryder, M Aldersley, D Mutimer, F Murray, PA McCormick, J Dillon, G Foster, K Agarwal, M Charafeddine, A Joy, L Liu, R-M Stanica, T Pilot-Matias, M O’Meara, C Pollard, DE Cohen, S Norris

Gut Jul 2017, 66 (Suppl 2) A5-A6; DOI: 10.1136/gutjnl-2017-314472.10
Highly bioavailable silibinin nanoparticles inhibit HCV infection
Ching-Hsuan Liu, Chun-Ching Lin, Wen-Chan Hsu, Chueh-Yao Chung, Chih-Chan Lin, Alagie Jassey, Shun-Pang Chang, Chen-Jei Tai, Cheng-Jeng Tai, Justin Shields, Christopher D Richardson, Ming-Hong Yen, D Lorne J Tyrrell, Liang-Tzung Lin

Gut Oct 2017, 66 (10) 1853-1861; DOI: 10.1136/gutjnl-2016-312019
Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses
Amélie Menard, Sarah Aherfi, Saadia Mokhtari, Catherine Dhiver, Isabelle Ravaux, Hervé Tissot-Dupont, Line Meddeb, Philippe Brouqui, Andreas Stein, Philippe Colson

Gut Oct 2017, 66 (10) 1868-1869; DOI: 10.1136/gutjnl-2016-313431
Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience
Hisham R El-Khayat, Yasser M Fouad, Mohsen Maher, Hussain El –Amin, Hala Muhammed

Gut Nov 2017, 66 (11) 2008-2012; DOI: 10.1136/gutjnl-2016-312012
Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene
Tsunamasa Watanabe, Fuminaka Sugauchi, Yasuhito Tanaka, Kentaro Matsuura, Hiroshi Yatsuhashi, Shuko Murakami, Sayuki Iijima, Etsuko Iio, Masaya Sugiyama, Takashi Shimada, Masakazu Kakuni, Michinori Kohara, Masashi Mizokami

Gut Sep 2013, 62 (9) 1340-1346; DOI: 10.1136/gutjnl-2012-302553

Main menu

HCV

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

HCV

Pages